Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2013

View Archived Issues

Lexicon Pharmaceuticals reports data on novel SGLT inhibitors for diabetes

The reclassification of endometrial carcinoma subgroup categorization on a genomic basis

Results of phase I expansion study of CC-223 reported

Preclinical data support therapeutic efficacy of UR-1102 for hyperuricemia and gout

Results from first-in-human study of VXM-01 reported

NOX-G16, a new candidate for type 1 diabetes

Roche presents novel agents for HCV infection

Forma Therapeutics and Cancer Research Technology to discover cancer drugs

Omthera Pharmaceuticals submits NDA for Epanova to the FDA

Boehringer Ingelheim discloses novel ACC-beta inhibitors

Lorus Therapeutics reports phase I data for LOR-253

Novel CRTH2 receptor antagonists prepared by Actelion Pharmaceuticals

Bellicum Pharmaceuticals begins trial of novel controlled dendritic cell immunotherapy

Chelsea Therapeutics resubmits Northera NDA

Olema Pharmaceuticals divulges new estrogen receptor modulators

Immunocore and GSK partner to discover ImmTACs against novel targets

Imetelstat shows promise in phase II trial for the treatment of essential thrombocythemia

Acorda Therapeutics acquires two neuropathic pain assets

Sensorion and Griffin receive Eurostars grant to develop new therapies for vestibular disorders

Sorrento and Ben-Gurion University sign agreement to develop anti-HCV antibodies

Calimmune commences phase I/II trial of gene medicine for HIV

Nuvilex to advance cell-encapsulated anticancer drug to phase III trials

Advancell grants Helsinn worldwide license to drug for chemotherapy-induced dermatological injuries

Kinex Pharmaceuticals to lead Orascovery program development in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...